1
|
Zimmerman EA, Irani I, Chen P, Gal-Yam A, Schulze S, Perley DA, Sollerman J, Filippenko AV, Shenar T, Yaron O, Shahaf S, Bruch RJ, Ofek EO, De Cia A, Brink TG, Yang Y, Vasylyev SS, Ben Ami S, Aubert M, Badash A, Bloom JS, Brown PJ, De K, Dimitriadis G, Fransson C, Fremling C, Hinds K, Horesh A, Johansson JP, Kasliwal MM, Kulkarni SR, Kushnir D, Martin C, Matuzewski M, McGurk RC, Miller AA, Morag J, Neil JD, Nugent PE, Post RS, Prusinski NZ, Qin Y, Raichoor A, Riddle R, Rowe M, Rusholme B, Sfaradi I, Sjoberg KM, Soumagnac M, Stein RD, Strotjohann NL, Terwel JH, Wasserman T, Wise J, Wold A, Yan L, Zhang K. The complex circumstellar environment of supernova 2023ixf. Nature 2024; 627:759-762. [PMID: 38538936 DOI: 10.1038/s41586-024-07116-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Accepted: 01/24/2024] [Indexed: 04/01/2024]
Abstract
The early evolution of a supernova (SN) can reveal information about the environment and the progenitor star. When a star explodes in vacuum, the first photons to escape from its surface appear as a brief, hours-long shock-breakout flare1,2, followed by a cooling phase of emission. However, for stars exploding within a distribution of dense, optically thick circumstellar material (CSM), the first photons escape from the material beyond the stellar edge and the duration of the initial flare can extend to several days, during which the escaping emission indicates photospheric heating3. Early serendipitous observations2,4 that lacked ultraviolet (UV) data were unable to determine whether the early emission is heating or cooling and hence the nature of the early explosion event. Here we report UV spectra of the nearby SN 2023ixf in the galaxy Messier 101 (M101). Using the UV data as well as a comprehensive set of further multiwavelength observations, we temporally resolve the emergence of the explosion shock from a thick medium heated by the SN emission. We derive a reliable bolometric light curve that indicates that the shock breaks out from a dense layer with a radius substantially larger than typical supergiants.
Collapse
Affiliation(s)
- E A Zimmerman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel.
| | - I Irani
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - P Chen
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - A Gal-Yam
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - S Schulze
- The Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm, Sweden
| | - D A Perley
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool, UK
| | - J Sollerman
- The Oskar Klein Centre, Department of Astronomy, Stockholm University, AlbaNova, Stockholm, Sweden
| | - A V Filippenko
- Department of Astronomy, University of California, Berkeley, Berkeley, CA, USA
| | - T Shenar
- Departamento de Astrofísica, Centro de Astrobiología (CSIC-INTA), Madrid, Spain
| | - O Yaron
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - S Shahaf
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - R J Bruch
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel
| | - E O Ofek
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - A De Cia
- European Southern Observatory, Garching bei München, Germany
- Department of Astronomy, University of Geneva, Versoix, Switzerland
| | - T G Brink
- Department of Astronomy, University of California, Berkeley, Berkeley, CA, USA
| | - Y Yang
- Department of Astronomy, University of California, Berkeley, Berkeley, CA, USA
- Physics Department and Tsinghua Center for Astrophysics (THCA), Tsinghua University, Beijing, China
| | - S S Vasylyev
- Department of Astronomy, University of California, Berkeley, Berkeley, CA, USA
| | - S Ben Ami
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - M Aubert
- Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
| | - A Badash
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - J S Bloom
- Department of Astronomy, University of California, Berkeley, Berkeley, CA, USA
| | - P J Brown
- Department of Physics and Astronomy, Texas A&M University, College Station, TX, USA
| | - K De
- MIT Kavli Institute for Astrophysics and Space Research, Cambridge, MA, USA
| | - G Dimitriadis
- School of Physics, Trinity College Dublin, The University of Dublin, Dublin 2, Ireland
| | - C Fransson
- The Oskar Klein Centre, Department of Astronomy, Stockholm University, AlbaNova, Stockholm, Sweden
| | - C Fremling
- Caltech Optical Observatories, California Institute of Technology, Pasadena, CA, USA
- Division of Physics, Mathematics and Astronomy, California Institute of Technology, Pasadena, CA, USA
| | - K Hinds
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool, UK
| | - A Horesh
- The Racah Institute of Physics, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - J P Johansson
- The Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm, Sweden
| | - M M Kasliwal
- Division of Physics, Mathematics and Astronomy, California Institute of Technology, Pasadena, CA, USA
| | - S R Kulkarni
- Division of Physics, Mathematics and Astronomy, California Institute of Technology, Pasadena, CA, USA
| | - D Kushnir
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - C Martin
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - M Matuzewski
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - R C McGurk
- W. M. Keck Observatory, Kamuela, HI, USA
| | - A A Miller
- Department of Physics and Astronomy, Northwestern University, Evanston, IL, USA
- Center for Interdisciplinary Exploration and Research in Astrophysics (CIERA), Northwestern University, Evanston, IL, USA
| | - J Morag
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - J D Neil
- Division of Physics, Mathematics and Astronomy, California Institute of Technology, Pasadena, CA, USA
| | - P E Nugent
- Department of Astronomy, University of California, Berkeley, Berkeley, CA, USA
- Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - R S Post
- Post Observatory, Lexington, MA, USA
| | - N Z Prusinski
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - Y Qin
- Division of Physics, Mathematics and Astronomy, California Institute of Technology, Pasadena, CA, USA
| | - A Raichoor
- Department of Astronomy, University of California, Berkeley, Berkeley, CA, USA
| | - R Riddle
- Caltech Optical Observatories, California Institute of Technology, Pasadena, CA, USA
| | - M Rowe
- Department of Physics and Astronomy, Texas A&M University, College Station, TX, USA
| | - B Rusholme
- IPAC, California Institute of Technology, Pasadena, CA, USA
| | - I Sfaradi
- The Racah Institute of Physics, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - K M Sjoberg
- Department of Astronomy, Harvard University, Cambridge, MA, USA
- Isaac Newton Group (ING), Santa Cruz de La Palma, Canary Islands, Spain
| | - M Soumagnac
- Lawrence Berkeley National Laboratory, Berkeley, CA, USA
- Department of Physics, Bar-Ilan University, Ramat Gan, Israel
| | - R D Stein
- Division of Physics, Mathematics and Astronomy, California Institute of Technology, Pasadena, CA, USA
| | - N L Strotjohann
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - J H Terwel
- School of Physics, Trinity College Dublin, The University of Dublin, Dublin 2, Ireland
- Isaac Newton Group (ING), Santa Cruz de La Palma, Canary Islands, Spain
| | - T Wasserman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel
| | - J Wise
- Astrophysics Research Institute, Liverpool John Moores University, Liverpool, UK
| | - A Wold
- IPAC, California Institute of Technology, Pasadena, CA, USA
| | - L Yan
- Caltech Optical Observatories, California Institute of Technology, Pasadena, CA, USA
| | - K Zhang
- Department of Astronomy, University of California, Berkeley, Berkeley, CA, USA
- Department of Astronomy & Astrophysics, University of California, San Diego, La Jolla, CA, USA
| |
Collapse
|
2
|
Barbirou M, Miller AA, Mezlini A, Bouhaouala-Zahar B, Tonellato PJ. Variant Characterization of a Representative Large Pedigree Suggests "Variant Risk Clusters" Convey Varying Predisposition of Risk to Lynch Syndrome. Cancers (Basel) 2023; 15:4074. [PMID: 37627102 PMCID: PMC10452890 DOI: 10.3390/cancers15164074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 08/09/2023] [Accepted: 08/10/2023] [Indexed: 08/27/2023] Open
Abstract
Recently, worldwide incidences of young adult aggressive colorectal cancer (CRC) have rapidly increased. Of these incidences diagnosed as familial Lynch syndrome (LS) CRC, outcomes are extremely poor. In this study, we seek novel familial germline variants from a large pedigree Tunisian family with 12 LS-affected individuals to identify putative germline variants associated with varying risk of LS. Whole-genome sequencing analysis was performed to identify known and novel germline variants shared between affected and non-affected pedigree members. SNPs, indels, and structural variants (SVs) were computationally identified, and their oncological influence was predicted using the Genetic Association of Complex Diseases and Disorders, OncoKB, and My Cancer Genome databases. Of 94 germline familial variants identified with predicted functional impact, 37 SNPs/indels were detected in 28 genes, 2 of which (MLH1 and PRH1-TAS2R14) have known association with CRC and 4 others (PPP1R13B, LAMA5, FTO, and NLRP14) have known association with non-CRC cancers. In addition, 48 of 57 identified SVs overlap with 43 genes. Three of these genes (RELN, IRS2, and FOXP1) have a known association with non-CRC digestive cancers and one (RRAS2) has a known association with non-CRC cancer. Our study identified 83 novel, predicted functionally impactful germline variants grouped in three "variant risk clusters" shared in three familiarly associated LS groups (high, intermediate and low risk). This variant characterization study demonstrates that large pedigree investigations provide important evidence supporting the hypothesis that different "variant risk clusters" can convey different mechanisms of risk and oncogenesis of LS-CRC even within the same pedigree.
Collapse
Affiliation(s)
- Mouadh Barbirou
- Circulating Tumor Cell Core Laboratory, Population Science Division, Medical Oncology Department, Medical College, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA;
- Center for Biomedical Informatics, Department of Health Management and Informatics, School of Medicine, University of Missouri, Columbia, MI 65211, USA;
- Medical School, University of Tunis El Manar, Tunis 1068, Tunisia;
| | - Amanda A. Miller
- Circulating Tumor Cell Core Laboratory, Population Science Division, Medical Oncology Department, Medical College, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA;
- Center for Biomedical Informatics, Department of Health Management and Informatics, School of Medicine, University of Missouri, Columbia, MI 65211, USA;
| | - Amel Mezlini
- Medical Oncology Division, Salah Azeiz Oncology Institute, University of Tunis El Manar, Tunis 1068, Tunisia;
| | - Balkiss Bouhaouala-Zahar
- Medical School, University of Tunis El Manar, Tunis 1068, Tunisia;
- Laboratory of Venoms and Therapeutic Biomolecules, LR16IPT08 Institute Pasteur of Tunis, University of Tunis El Manar, Tunis 1068, Tunisia
| | - Peter J. Tonellato
- Center for Biomedical Informatics, Department of Health Management and Informatics, School of Medicine, University of Missouri, Columbia, MI 65211, USA;
| |
Collapse
|
3
|
Ivanova VV, Mil'to IV, Sukhodolo IV, Miller AA. Ultrastructural Characteristics of the Testicular Interstitial Endocrinocytes of Adult Rats Subjected to Total Sialoadenectomy. Bull Exp Biol Med 2018; 165:280-283. [PMID: 29931628 DOI: 10.1007/s10517-018-4148-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Indexed: 11/25/2022]
Abstract
The major salivary glands of rats release into the saliva and blood a wide spectrum of bioactive substances, essential for many organs, including the testes. Sialoadenectomy leads to the development of degenerative changes in the cells of the twisted testicular tubules. However, the effects of bioactive factors released by the major salivary glands on the morphology and function of Leydig cells remain little studied. Sialoadenectomy in adult rats led (in 1-4 weeks) to a decrease in the nuclear and cytoplasmatic areas of Leydig cells, violation of the plasmalemma integrity, dilatation of perinuclear space and agranular endoplasmatic reticulum vesicles, and to destruction of the mitochondria. Ultrastructural changes caused by sialoadenectomy completely resolved by week 6 of the experiment at the expense of compensatory activation of the synthesis of the major salivary gland factors by other sources in the organism of rats.
Collapse
Affiliation(s)
- V V Ivanova
- Department of Morphology and General Pathology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia.
| | - I V Mil'to
- Department of Morphology and General Pathology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia.,Department of Biotechnology and Organic Chemistry, Tomsk National Research Polytechnological University, Tomsk, Russia
| | - I V Sukhodolo
- Department of Morphology and General Pathology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia
| | - A A Miller
- Department of Morphology and General Pathology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia
| |
Collapse
|
4
|
Kasliwal MM, Nakar E, Singer LP, Kaplan DL, Cook DO, Van Sistine A, Lau RM, Fremling C, Gottlieb O, Jencson JE, Adams SM, Feindt U, Hotokezaka K, Ghosh S, Perley DA, Yu PC, Piran T, Allison JR, Anupama GC, Balasubramanian A, Bannister KW, Bally J, Barnes J, Barway S, Bellm E, Bhalerao V, Bhattacharya D, Blagorodnova N, Bloom JS, Brady PR, Cannella C, Chatterjee D, Cenko SB, Cobb BE, Copperwheat C, Corsi A, De K, Dobie D, Emery SWK, Evans PA, Fox OD, Frail DA, Frohmaier C, Goobar A, Hallinan G, Harrison F, Helou G, Hinderer T, Ho AYQ, Horesh A, Ip WH, Itoh R, Kasen D, Kim H, Kuin NPM, Kupfer T, Lynch C, Madsen K, Mazzali PA, Miller AA, Mooley K, Murphy T, Ngeow CC, Nichols D, Nissanke S, Nugent P, Ofek EO, Qi H, Quimby RM, Rosswog S, Rusu F, Sadler EM, Schmidt P, Sollerman J, Steele I, Williamson AR, Xu Y, Yan L, Yatsu Y, Zhang C, Zhao W. Illuminating gravitational waves: A concordant picture of photons from a neutron star merger. Science 2017; 358:1559-1565. [PMID: 29038373 DOI: 10.1126/science.aap9455] [Citation(s) in RCA: 441] [Impact Index Per Article: 63.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Accepted: 10/05/2017] [Indexed: 11/02/2022]
Abstract
Merging neutron stars offer an excellent laboratory for simultaneously studying strong-field gravity and matter in extreme environments. We establish the physical association of an electromagnetic counterpart (EM170817) with gravitational waves (GW170817) detected from merging neutron stars. By synthesizing a panchromatic data set, we demonstrate that merging neutron stars are a long-sought production site forging heavy elements by r-process nucleosynthesis. The weak gamma rays seen in EM170817 are dissimilar to classical short gamma-ray bursts with ultrarelativistic jets. Instead, we suggest that breakout of a wide-angle, mildly relativistic cocoon engulfing the jet explains the low-luminosity gamma rays, the high-luminosity ultraviolet-optical-infrared, and the delayed radio and x-ray emission. We posit that all neutron star mergers may lead to a wide-angle cocoon breakout, sometimes accompanied by a successful jet and sometimes by a choked jet.
Collapse
Affiliation(s)
- M M Kasliwal
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA.
| | - E Nakar
- The Raymond and Beverly Sackler School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - L P Singer
- Astroparticle Physics Laboratory, NASA Goddard Space Flight Center, Mail Code 661, Greenbelt, MD 20771, USA.,Joint Space-Science Institute, University of Maryland, College Park, MD 20742, USA
| | - D L Kaplan
- Department of Physics, University of Wisconsin, Milwaukee, WI 53201, USA
| | - D O Cook
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - A Van Sistine
- Department of Physics, University of Wisconsin, Milwaukee, WI 53201, USA
| | - R M Lau
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - C Fremling
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - O Gottlieb
- The Raymond and Beverly Sackler School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - J E Jencson
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - S M Adams
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - U Feindt
- The Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, SE-106 91 Stockholm, Sweden
| | - K Hotokezaka
- Center for Computational Astrophysics, Simons Foundation, Flatiron Institute, 162 5th Avenue, New York, NY 10010, USA.,Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, NJ 08544, USA
| | - S Ghosh
- Department of Physics, University of Wisconsin, Milwaukee, WI 53201, USA
| | - D A Perley
- Astrophysics Research Institute, Liverpool John Moores University, IC2, Liverpool Science Park, 146 Browlow Hill, Liverpool L3 5RF, UK
| | - P-C Yu
- Graduate Institute of Astronomy, National Central University, No. 300, Zhongda Road, Zhongli District, Taoyuan City 32001, Taiwan
| | - T Piran
- Racah Institute of Physics, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | - J R Allison
- Sydney Institute for Astronomy, School of Physics A28, The University of Sydney, New South Wales 2006, Australia.,Australian Research Council Centre of Excellence for All-sky Astrophysics in 3 Dimensions, Australia
| | - G C Anupama
- Indian Institute of Astrophysics, II Block Koramangala, Bangalore 560034, India
| | - A Balasubramanian
- Indian Institute of Science Education and Research, Dr. Homi Bhabha Road, Pashan, Pune 411008, India
| | - K W Bannister
- Australia Telescope National Facility, Astronomy and Space Science, Commonwealth Scientific and Industrial Research Organisation, Post Office Box 76, Epping, New South Wales 1710, Australia
| | - J Bally
- Department of Astrophysical and Planetary Sciences, University of Colorado, Boulder, CO 80305, USA
| | - J Barnes
- Columbia Astrophysics Laboratory, Columbia University, New York, NY 10027, USA
| | - S Barway
- South African Astronomical Observatory, Post Office Box 9, Observatory, Cape Town 7935, South Africa
| | - E Bellm
- Department of Astronomy, University of Washington, Seattle, WA 98195, USA
| | - V Bhalerao
- Department of Physics, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - D Bhattacharya
- Inter-University Centre for Astronomy and Astrophysics, Post Office Bag 4, Ganeshkhind, Pune 411007, India
| | - N Blagorodnova
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - J S Bloom
- Department of Astronomy, University of California, Berkeley, CA 94720-3411, USA.,Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS 50B-4206, Berkeley, CA 94720, USA
| | - P R Brady
- Department of Physics, University of Wisconsin, Milwaukee, WI 53201, USA
| | - C Cannella
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - D Chatterjee
- Department of Physics, University of Wisconsin, Milwaukee, WI 53201, USA
| | - S B Cenko
- Astroparticle Physics Laboratory, NASA Goddard Space Flight Center, Mail Code 661, Greenbelt, MD 20771, USA.,Joint Space-Science Institute, University of Maryland, College Park, MD 20742, USA
| | - B E Cobb
- Department of Physics, George Washington University, Washington, DC 20052, USA
| | - C Copperwheat
- Astrophysics Research Institute, Liverpool John Moores University, IC2, Liverpool Science Park, 146 Browlow Hill, Liverpool L3 5RF, UK
| | - A Corsi
- Department of Physics and Astronomy, Texas Tech University, Box 41051, Lubbock, TX 79409-1051, USA
| | - K De
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - D Dobie
- Sydney Institute for Astronomy, School of Physics A28, The University of Sydney, New South Wales 2006, Australia.,Australian Research Council Centre of Excellence for All-sky Astrophysics, Australia.,Australia Telescope National Facility, Astronomy and Space Science, Commonwealth Scientific and Industrial Research Organisation, Post Office Box 76, Epping, New South Wales 1710, Australia
| | - S W K Emery
- University College London, Mullard Space Science Laboratory, Holmbury St. Mary, Dorking RH5 6NT, UK
| | - P A Evans
- X-ray and Observational Astronomy Research Group, Leicester Institute for Space and Earth Observation, Department of Physics and Astronomy, University of Leicester, University Road, Leicester, LE1 7RH, UK
| | - O D Fox
- Space Telescope Science Institute, 3700 San Martin Drive, Baltimore, MD 21218, USA
| | - D A Frail
- National Radio Astronomy Observatory, Socorro, NM 87825, USA
| | - C Frohmaier
- Department of Physics and Astronomy, University of Southampton, Southampton, Hampshire SO17 1BJ, UK.,Institute of Cosmology and Gravitation, Dennis Sciama Building, University of Portsmouth, Burnaby Road, Portsmouth PO1 3FX, UK
| | - A Goobar
- The Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, SE-106 91 Stockholm, Sweden
| | - G Hallinan
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - F Harrison
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - G Helou
- Infrared Processing and Analysis Center, California Institute of Technology, Pasadena, CA 91125, USA
| | - T Hinderer
- Institute of Mathematics, Astrophysics and Particle Physics, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, Netherlands
| | - A Y Q Ho
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - A Horesh
- Racah Institute of Physics, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | - W-H Ip
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, NJ 08544, USA
| | - R Itoh
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8551, Japan
| | - D Kasen
- Department of Astronomy, University of California, Berkeley, CA 94720-3411, USA.,Department of Physics, University of California, Berkeley, CA 94720, USA
| | - H Kim
- Gemini Observatory, Casilla 603, La Serena, Chile
| | - N P M Kuin
- University College London, Mullard Space Science Laboratory, Holmbury St. Mary, Dorking RH5 6NT, UK
| | - T Kupfer
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - C Lynch
- Sydney Institute for Astronomy, School of Physics A28, The University of Sydney, New South Wales 2006, Australia.,Australian Research Council Centre of Excellence for All-sky Astrophysics, Australia
| | - K Madsen
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - P A Mazzali
- Astrophysics Research Institute, Liverpool John Moores University, IC2, Liverpool Science Park, 146 Browlow Hill, Liverpool L3 5RF, UK.,Max-Planck Institute for Astrophysics, Garching, Germany
| | - A A Miller
- Center for Interdisciplinary Exploration and Research in Astrophysics and Department of Physics and Astronomy, Northwestern University, Evanston, IL 60208, USA.,The Adler Planetarium, Chicago, IL 60605, USA
| | - K Mooley
- Astrophysics, Department of Physics, University of Oxford, Keble Road, Oxford OX1 3RH, UK
| | - T Murphy
- Sydney Institute for Astronomy, School of Physics A28, The University of Sydney, New South Wales 2006, Australia.,Australian Research Council Centre of Excellence for All-sky Astrophysics, Australia
| | - C-C Ngeow
- Graduate Institute of Astronomy, National Central University, No. 300, Zhongda Road, Zhongli District, Taoyuan City 32001, Taiwan
| | - D Nichols
- Institute of Mathematics, Astrophysics and Particle Physics, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, Netherlands
| | - S Nissanke
- Institute of Mathematics, Astrophysics and Particle Physics, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, Netherlands
| | - P Nugent
- Department of Astronomy, University of California, Berkeley, CA 94720-3411, USA.,Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS 50B-4206, Berkeley, CA 94720, USA
| | - E O Ofek
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - H Qi
- Department of Physics, University of Wisconsin, Milwaukee, WI 53201, USA
| | - R M Quimby
- Department of Astronomy, San Diego State University, San Diego, CA 92182, USA.,Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - S Rosswog
- The Oskar Klein Centre, Department of Astronomy, Stockholm University, AlbaNova, SE-106 91 Stockholm, Sweden
| | - F Rusu
- School of Engineering (EECS), University of California, Merced, CA 95343, USA
| | - E M Sadler
- Sydney Institute for Astronomy, School of Physics A28, The University of Sydney, New South Wales 2006, Australia.,Australian Research Council Centre of Excellence for All-sky Astrophysics, Australia
| | - P Schmidt
- Institute of Mathematics, Astrophysics and Particle Physics, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, Netherlands
| | - J Sollerman
- The Oskar Klein Centre, Department of Astronomy, Stockholm University, AlbaNova, SE-106 91 Stockholm, Sweden
| | - I Steele
- Astrophysics Research Institute, Liverpool John Moores University, IC2, Liverpool Science Park, 146 Browlow Hill, Liverpool L3 5RF, UK
| | - A R Williamson
- Institute of Mathematics, Astrophysics and Particle Physics, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, Netherlands
| | - Y Xu
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
| | - L Yan
- Division of Physics, Math and Astronomy, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA.,Infrared Processing and Analysis Center, California Institute of Technology, Pasadena, CA 91125, USA
| | - Y Yatsu
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8551, Japan
| | - C Zhang
- Department of Physics, University of Wisconsin, Milwaukee, WI 53201, USA
| | - W Zhao
- School of Engineering (EECS), University of California, Merced, CA 95343, USA
| |
Collapse
|
5
|
Goobar A, Amanullah R, Kulkarni SR, Nugent PE, Johansson J, Steidel C, Law D, Mörtsell E, Quimby R, Blagorodnova N, Brandeker A, Cao Y, Cooray A, Ferretti R, Fremling C, Hangard L, Kasliwal M, Kupfer T, Lunnan R, Masci F, Miller AA, Nayyeri H, Neill JD, Ofek EO, Papadogiannakis S, Petrushevska T, Ravi V, Sollerman J, Sullivan M, Taddia F, Walters R, Wilson D, Yan L, Yaron O. iPTF16geu: A multiply imaged, gravitationally lensed type Ia supernova. Science 2017; 356:291-295. [PMID: 28428419 DOI: 10.1126/science.aal2729] [Citation(s) in RCA: 139] [Impact Index Per Article: 19.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Accepted: 03/24/2017] [Indexed: 11/02/2022]
Abstract
We report the discovery of a multiply imaged, gravitationally lensed type Ia supernova, iPTF16geu (SN 2016geu), at redshift z = 0.409. This phenomenon was identified because the light from the stellar explosion was magnified more than 50 times by the curvature of space around matter in an intervening galaxy. We used high-spatial-resolution observations to resolve four images of the lensed supernova, approximately 0.3 arc seconds from the center of the foreground galaxy. The observations probe a physical scale of ~1 kiloparsec, smaller than is typical in other studies of extragalactic gravitational lensing. The large magnification and symmetric image configuration imply close alignment between the lines of sight to the supernova and to the lens. The relative magnifications of the four images provide evidence for substructures in the lensing galaxy.
Collapse
Affiliation(s)
- A Goobar
- Oskar Klein Centre, Department of Physics, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden.
| | - R Amanullah
- Oskar Klein Centre, Department of Physics, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - S R Kulkarni
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - P E Nugent
- Department of Astronomy, University of California, Berkeley, CA 94720, USA.,MS 50B-4206, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - J Johansson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - C Steidel
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - D Law
- Space Telescope Science Institute, Baltimore, MD 21218, USA
| | - E Mörtsell
- Oskar Klein Centre, Department of Physics, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - R Quimby
- Department of Astronomy, San Diego State University, San Diego, CA 92182, USA.,Kavli IPMU (WPI), University of Tokyo Institutes for Advanced Study, Kashiwa, Chiba 277-8583, Japan
| | - N Blagorodnova
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - A Brandeker
- Department of Astronomy, Stockholm University, Albanova, SE 10691 Stockholm, Sweden
| | - Y Cao
- eScience Institute and Department of Astronomy, University of Washington, Seattle, WA 98195, USA
| | - A Cooray
- Department of Physics and Astronomy, University of California, Irvine, CA 92697, USA
| | - R Ferretti
- Oskar Klein Centre, Department of Physics, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - C Fremling
- Oskar Klein Centre, Department of Astronomy, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - L Hangard
- Oskar Klein Centre, Department of Physics, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - M Kasliwal
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - T Kupfer
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - R Lunnan
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA.,Department of Astronomy, Stockholm University, Albanova, SE 10691 Stockholm, Sweden
| | - F Masci
- Infrared Processing and Analysis Center, California Institute of Technology, Pasadena, CA 91125, USA
| | - A A Miller
- Center for Interdisciplinary Exploration and Research in Astrophysics and Department of Physics and Astronomy, Northwestern University, Evanston, IL 60208, USA.,Adler Planetarium, Chicago, IL 60605, USA
| | - H Nayyeri
- Department of Physics and Astronomy, University of California, Irvine, CA 92697, USA
| | - J D Neill
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - E O Ofek
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Papadogiannakis
- Oskar Klein Centre, Department of Physics, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - T Petrushevska
- Oskar Klein Centre, Department of Physics, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - V Ravi
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - J Sollerman
- Oskar Klein Centre, Department of Astronomy, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - M Sullivan
- Department of Physics and Astronomy, University of Southampton, Southampton SO17 1BJ, UK
| | - F Taddia
- Oskar Klein Centre, Department of Astronomy, Stockholm University, Albanova University Center, SE 106 91 Stockholm, Sweden
| | - R Walters
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - D Wilson
- Department of Physics and Astronomy, University of California, Irvine, CA 92697, USA
| | - L Yan
- Cahill Center for Astrophysics, California Institute of Technology, Pasadena, CA 91125, USA
| | - O Yaron
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| |
Collapse
|
6
|
Li CH, Bies RR, Wang Y, Sharma MR, Karovic S, Werk L, Edelman MJ, Miller AA, Vokes EE, Oto A, Ratain MJ, Schwartz LH, Maitland ML. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. Clin Transl Sci 2016; 9:43-50. [PMID: 26790562 PMCID: PMC4760886 DOI: 10.1111/cts.12384] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Revised: 12/14/2015] [Accepted: 12/16/2015] [Indexed: 01/12/2023] Open
Abstract
Quantitative assessments of tumor burden and modeling of longitudinal growth could improve phase II oncology trials. To identify obstacles to wider use of quantitative measures we obtained recorded linear tumor measurements from three published lung cancer trials. Model-based parameters of tumor burden change were estimated and compared with similarly sized samples from separate trials. Time-to-tumor growth (TTG) was computed from measurements recorded on case report forms and a second radiologist blinded to the form data. Response Evaluation Criteria in Solid Tumors (RECIST)-based progression-free survival (PFS) measures were perfectly concordant between the original forms data and the blinded radiologist re-evaluation (intraclass correlation coefficient = 1), but these routine interrater differences in the identification and measurement of target lesions were associated with an average 18-week delay (range, -20 to 55 weeks) in TTG (intraclass correlation coefficient = 0.32). To exploit computational metrics for improving statistical power in small clinical trials will require increased precision of tumor burden assessments.
Collapse
Affiliation(s)
- C H Li
- Indiana University School of Medicine, Indianapolis, Indiana, USA.,Indiana Clinical and Translational Sciences Institute (CTSI), Indianapolis, Indiana, USA
| | - R R Bies
- Indiana University School of Medicine, Indianapolis, Indiana, USA.,Indiana Clinical and Translational Sciences Institute (CTSI), Indianapolis, Indiana, USA.,Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA
| | - Y Wang
- Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, Maryland, USA
| | - M R Sharma
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA
| | - S Karovic
- University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA
| | - L Werk
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,Duke University, Durham, North Carolina, USA
| | - M J Edelman
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,University of Maryland Greenebaum Cancer Center, School of Medicine, Baltimore, Maryland, USA
| | - A A Miller
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
| | - E E Vokes
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA
| | - A Oto
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA
| | - M J Ratain
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA
| | - L H Schwartz
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - M L Maitland
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.,University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA
| |
Collapse
|
7
|
Simakova AV, Miller AA. ULTRASTRUCTURAL DIFFERENCES OF PRESPORES DEVELOPMENTAL STAGES AND MEIOSPORES OF SPECIES OF CLOSELY RELATED MICROSPORIDIA OF GENERA AMBLYOSPORA AND TRICHOCTOSPOREA (AMBLYOSPORIDAE: MICROSPORIDIA) FROM BLOOD-SUKING MOSQUITOES OF THE GENUS AEDES (DIPTERA: CULICIDAE). Tsitologiia 2016; 58:799-805. [PMID: 30199155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Ultrastructure of prespore developmental stages, with emphasis on meiospores, has been examined in closely related genera of Microsporidia, Amblyospora and Trichoctosporea, isolated from larvae adipose tissue of mosquitoes Aedes in order to compare morphology of these parasites. Ultrastructural differences between Amblyospora and Trichoctosporea have been found to concern the secret filling episporal space of sporophorous vesicle, wall of mature spores, the polaroplast and membranes of thin coils of polar tubes. The episporal secret contributes to formation of meiospore wall and its structure is one of key systematic features to be considered in the identification of microsporidia.
Collapse
|
8
|
Miller AA, D'yachkova IM, Davydkin VI, Golubev AG, Ippolitova EI. [Cyst of round ligament of liver as a cause of pain syndrome in the right hypochondrium]. Vestn Khir Im I I Grek 2016; 175:86-89. [PMID: 30444101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
|
9
|
Duce JA, Ayton S, Miller AA, Tsatsanis A, Lam LQ, Leone L, Corbin JE, Butzkueven H, Kilpatrick TJ, Rogers JT, Barnham KJ, Finkelstein DI, Bush AI. Amine oxidase activity of β-amyloid precursor protein modulates systemic and local catecholamine levels. Mol Psychiatry 2013; 18:245-54. [PMID: 22212595 DOI: 10.1038/mp.2011.168] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The catecholamines dopamine (DA), norepinephrine (NE) and epinephrine (E) are neurotransmitters and hormones that mediate stress responses in tissues and plasma. The expression of β-amyloid precursor protein (APP) is responsive to stress and is high in tissues rich in catecholamines. We recently reported that APP is a ferroxidase, subsuming, in neurons and other cells, the iron-export activity that ceruloplasmin mediates in glia. Here we report that, like ceruloplasmin, APP also oxidizes synthetic amines and catecholamines catalytically (K(m) NE=0.27 mM), through a site encompassing its ferroxidase motif and selectively inhibited by zinc. Accordingly, APP knockout mice have significantly higher levels of DA, NE and E in brain, plasma and select tissues. Consistent with this, these animals have increased resting heart rate and systolic blood pressure as well as suppressed prolactin and lymphocyte levels. These findings support a role for APP in extracellular catecholaminergic clearance.
Collapse
Affiliation(s)
- J A Duce
- The Mental Health Research Institute, The University of Melbourne, Parkville, VIC, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Rat liver was examined by transmission electron microscopy after a single intravenous injection of nanosized magnetite suspension (0.1 g (Fe(3)O(4))/kg body weight). Magnetite particles were found in Kupffer's cells and hepatocytes. Accumulation of the particles by these two cell types was different. Morphometry of magnetite-containing granules in Kupffer's cells and nanoparticle agglomerations in hepatocytes was carried out. The ultrastructure of Kupffer's cell granules was described and the mechanism of penetration of nanosized magnetite particles into the cells was suggested. Nanosized magnetite particles were not completely eliminated over 40 days after a single injection.
Collapse
Affiliation(s)
- I V Mil'to
- Department of Morphology and General Pathology, Siberian State Medical University, Ministry of Health and Social Development of the Russian Federation, Tomsk, Russia.
| | | | | |
Collapse
|
11
|
Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond GR, Sobey CG. Reduction of cerebral infarct volume by apocynin requires pretreatment and is absent in Nox2-deficient mice. Br J Pharmacol 2009; 156:680-8. [PMID: 19175604 DOI: 10.1111/j.1476-5381.2008.00073.x] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND AND PURPOSE Reactive oxygen species (ROS) derived from Nox2-containing reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity is reportedly detrimental in cerebrovascular disease. However, ROS generation by other Nox isoforms may have a physiological role. No Nox2-selective inhibitors have yet been identified, and thus it is unclear whether isoform non-selective Nox inhibitors would necessarily improve outcome after stroke. We assessed the effect of apocynin on cerebrovascular ROS production and also on outcome following cerebral ischaemia when administered either before ischaemia or after cerebral reperfusion. The involvement of Nox2-containing NADPH oxidase in the effects of apocynin was assessed using Nox2(-/-) mice. EXPERIMENTAL APPROACH Transient cerebral ischaemia was induced by 0.5 h middle cerebral artery occlusion followed by 23.5 h reperfusion. Mice received apocynin (2.5 mg.kg(-1), i.p.) either 0.5 h before ischaemia or 1 h after reperfusion. In situ superoxide production after cerebral ischaemia-reperfusion was measured in brain sections of wild-type mice at 24 h using dihydroethidium fluorescence. KEY RESULTS Treatment with apocynin 0.5 h before ischaemia reduced total infarct volume, neurological impairment and mortality in wild-type but not Nox2(-/-) mice. Conversely, treatment with apocynin 1 h after initiation of reperfusion had no protective effect. Cerebral ischaemia and reperfusion increased superoxide production in the brain at 24 h, and pretreatment but not posttreatment with apocynin reduced superoxide levels. CONCLUSIONS AND IMPLICATIONS Apocynin improves outcome following stroke when administered before ischaemia in wild-type but not Nox2(-/-) mice.
Collapse
Affiliation(s)
- K A Jackman
- Department of Pharmacology, Monash University, Clayton, VIC, Australia
| | | | | | | | | | | |
Collapse
|
12
|
Miller AA, Simakova AV. [Use of the OTE-staining method for ultrathin sections on the example of microsporidia (Protozoa: Microsporidia)]. Tsitologiia 2009; 51:741-747. [PMID: 19899706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A novel method for staining ultrathin sections and examining organelles of taxonomic importance in microsporidian parasites was evaluated using oolong tea extract (OTE) and compared with traditional staining with uranyl acetate (UA). All basic intracellular structures of taxonomic significance were effectively stained with the OTE-staining method and additional layers of the polar filament with more clear boundaries between them were revealed. However, greater resolution and higher general contrast of several structures including membranes, layers of the envelope of mature spores, the structure of rough endoplasmic reticulum, Golgi complex, and nuclear chromatin were achieved with traditional UA-staining. The OTE-staining method has the advantage of being safe and preparations can be stored in light at room temperature with no loss in staining properties. However, greater staining time is required. We conclude that the OTE-staining method may be used as an alternative to traditional staining with UA with successful results.
Collapse
|
13
|
Budzyn K, Ravi RM, Miller AA, Sobey CG. Mechanisms of augmented vasoconstriction induced by 5-hydroxytryptamine in aortic rings from spontaneously hypertensive rats. Br J Pharmacol 2008; 155:210-6. [PMID: 18552867 DOI: 10.1038/bjp.2008.247] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND AND PURPOSE To test whether development of enhanced vasoconstriction to 5-hydroxytryptamine (5-HT; serotonin) in SHR was temporally related to hypertension, elevated vascular superoxide (O(2)(-)) levels, decreased NO bioavailability, or increased contractile effects of cyclooxygenase or rho-kinase and/or PKC. EXPERIMENTAL APPROACH We examined systolic blood pressure (SBP), vascular O(2)(-), and 5-HT-induced contractile responses of aortic segments from 4- and 8-week-old WKY and SHR. KEY RESULTS SBP was 35% higher in SHR than WKY at 4 weeks and 60% higher at 8 weeks. Contractile responses to 5-HT were similar in WKY and SHR at 4 weeks, but were markedly augmented in SHR at 8 weeks. The NO synthase inhibitor, L-NAME, enhanced contractile responses to 5-HT markedly in both strains at 4 weeks and in WKY at 8 weeks, but only very modestly in SHR at 8 weeks. These functional differences were associated with higher O(2)(-) levels in SHR versus WKY at 8 weeks, but not at 4 weeks. The rho-kinase inhibitor, Y-27632, and the PKC inhibitor, Ro 31-8220, each only modestly attenuated contractions in WKY and SHR in each age group, and their effects in each strain were more pronounced at 8 weeks. The cyclooxygenase inhibitor, indomethacin, had no effect on contractile responses. CONCLUSIONS AND IMPLICATIONS Development of augmented vascular contractile responses to 5-HT in SHR is preceded by hypertension. It is associated with increased vascular O(2)(-) levels and reduced modulatory effects of NO, and is unlikely to be due to enhanced activity of rho-kinase, PKC or cyclooxygenase.
Collapse
Affiliation(s)
- K Budzyn
- Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia
| | | | | | | |
Collapse
|
14
|
Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM, Morton RF, Schild SE, Jett JR, Adjei AA. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005; 16:1811-6. [PMID: 16087693 DOI: 10.1093/annonc/mdi365] [Citation(s) in RCA: 101] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The aim of the present study was to evaluate the clinical activity of imatinib mesylate in patients with recurrent and refractory c-kit-expressing small-cell lung cancer. PATIENTS AND METHODS Patients with c-kit-expressing SCLC (> or =1+ by immunohistochemistry) were enrolled in two groups. Arm A included patients with disease progression <3 months and arm B included patients with disease progression > or =3 months after previous treatment. Imatinib was administered at a dose of 400 mg b.i.d. continuously, with a cycle length of 28 days. A single stage Simon design with a planned interim analysis was used to evaluate the 16-week progression free rate in each arm. RESULTS A total of 29 evaluable patients were entered into the study (seven in arm A, median age 68; 22 in arm B, median age 64.5). Median number of treatment cycles was one in both arms. Grade 3+ non-hematologic adverse events were seen in 15 (52%) patients, with nausea, vomiting, dyspnea, fatigue, anorexia and dehydration each occurring in at least 10% of patients. Median survival was 3.9 and 5.3 months and median time to progression was 1 and 1.1 months for arms A and B, respectively. Enrollment to arm A was temporarily suspended prior to reaching interim analysis due to striking early disease progression (29%), early deaths (29%) and patient refusal (42%). No objective responses and no confirmed stable disease > or =6 weeks were seen in either arm. Accrual was permanently terminated to both arms as only one patient was progression-free at 16 weeks. CONCLUSION Imatinib failed to demonstrate any clinical activity in spite of patient selection for c-kit-expressing SCLC. Our results strengthen the collective evidence that prediction of efficacy of novel therapeutic agents based on target expression, rather than pathway activation (for example, through activating mutations), may not be a valid paradigm for drug development.
Collapse
Affiliation(s)
- G K Dy
- Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Logvinov SV, Potapov AV, Varakuta EI, Drobatulina DA, Miller AA. [Effects of combined influence of ionizing radiation and light on the retina]. Radiats Biol Radioecol 2004; 44:666-71. [PMID: 15700807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
The continuous irradiation of rats with a light (3500 1x) for 48 hours led to destruction of 7.5 +/- 0.43% of neurosensoric cells (the control value was 0.2 +/- (0.02%). Longer photodamage caused progressing decrease in a population of the cells, narrowing followed by disappearance of corresponding layers of retina by the 30th day of the experiment. Preliminary exposure to X-rays with a dose of 5 Gy modified light damages of retina. The combination of two factors caused death of more than 30% of neurosensoric cells and redused the number of rows of nucleis of the external nuclear layer twice for the first 48 hours of illumination. After a longer influence of light a preliminary ionizing irradiation increased the number of destructively changed neurosensoric cells, reaching minimun of 41.7% by 30th day of the experiment. At the same time after a long combined irradiation less changes in row number quantity, numerical density of nucleus of the external nuclear layer and a population of neurosesoric cells in general was observed than after only one light exposure. Changes of choriocapillaries (thrombosis, obliteration, narrowing of a gap) which were more expressed at a combination of factors, led to infringement of blood circulation and played the important role in mechanisms of retina degeneration. Radial glia and neurons of internal layers of retina showed relative resistance to the investigated influences.
Collapse
|
16
|
Naslednikova IO, Riazantseva NV, Novitskiĭ VV, Tkachenko SB, Antoshina MA, Belokon' VV, Chernov AS, Reshetnikov VI, Shevtsova NM, Miller AA, Stepovaia EA. [The surface architectonics, functional characteristics, and metabolism in peripheral blood lymphocytes in acute herpes virus infection]. Klin Lab Diagn 2004:53-5. [PMID: 15230121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
Twenty-five patients (males--11, females--14; aged 18 to 45) with chronic herpes virus infection relapsing at the time of clinical tests were examined, including investigations of the surface architectonics, the ability to blast-transformation and the metabolic status of peripheral-blood lymphocytes. Chronic herpes virus infection was found to be concurrent with changes of the percentage ratio of lymphocytes with the surface micro-patterns of different types, with a more intense activity of the immunity T-chain and with a changed nature of the intracellular metabolism of lymphocyte cells.
Collapse
|
17
|
Naughton MJ, Herndon JE, Shumaker SA, Miller AA, Kornblith AB, Chao D, Holland J. The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Qual Life Res 2002; 11:235-48. [PMID: 12074261 DOI: 10.1023/a:1015257121369] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The purposes of this study were 2-fold: to evaluate the impact of the schedule dependency of etoposide (3-day IV short course vs. a 21-day oral prolonged course) with cisplatin on the quality of life of small-cell lung cancer (SCLC) patients; and to examine the effect of baseline quality of life variables on long-term survival, after adjustment for known demographic and clinical prognostic factors. Participants were 70 patients enrolled in the cancer and leukemia group B (CALGB) protocol 9033. Quality of life was assessed at baseline, 6 and 12 weeks by: the EORTC QLQ-30, the Centers for epidemiology studies--Depression short form, the medical outcomes study (MOS) social support questionnaire, and a scale of sleep quality. Contrary to expectations, study results suggested no significant differences in the patients' life quality and treatment response based on whether they received etoposide in a 3-day IV vs. a 21-day oral regimen. The use of the baseline variables in predicting overall survival indicated that patients who were non-white and with liver involvement had decreased survival. Brain involvement, being male, and higher depressive symptoms were also found to be borderline significant in predicting decreased survival in this patient population.
Collapse
Affiliation(s)
- M J Naughton
- Wake Forest University School of Medicine, Winston-Salem, NC 27157-1063, USA.
| | | | | | | | | | | | | |
Collapse
|
18
|
Ryazantseva NV, Novitskii VV, Stepovaya EA, Logvinov SV, Miller AA, Luk'yantsev SV. Ultrastructural changes in erythrocytes in patients with mental disorders. Bull Exp Biol Med 2001; 132:1013-6. [PMID: 11782808 DOI: 10.1023/a:1013696001474] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2001] [Indexed: 11/12/2022]
Abstract
Transmission electron microscopy of peripheral blood erythrocytes from patients with paranoid and residual schizophrenia, mental retardation, and neurotic disturbances revealed nonspecific ultrastructural changes in the membrane and matrix of red blood cells.
Collapse
|
19
|
Abstract
Inhibition of topoisomerase I by topotecan results in a compensatory increase in topoisomerase II levels associated with increased in vitro sensitivity of tumors to etoposide. Maximum synergy has been observed for the sequence of topotecan followed by etoposide. This is the pharmacologic rationale for the sequence of topotecan 0.4 mg/m(2) per day for 7 days continuous i.v. infusion, carboplatin i.v. on day 8, and etoposide 50 mg per day p.o. days 9 through 20. The carboplatin dosage was escalated from an AUC of 4 to 5 to 6 (Calvert formula). Up to six treatment cycles were administered at 28-day intervals. Eligible patients had metastatic non-small cell lung cancer (NSCLC) or extensive disease small lung cell lung cancer (SCLC), no prior chemotherapy, performance status 0-2, and adequate organ function. Follow-up was twice weekly in the first cycle for CBC and for topotecan and etoposide concentrations. Follow-up, thereafter, was weekly. Tumor response was assessed after two and six cycles and then as clinically indicated. At carboplatin AUCs of 4 and 5, no NCI grade 4 toxicity was observed in cycle 1 in cohorts of three patients each. At the AUC of 5, two patients experienced dose-limiting events after cycle 3, one grade 4 neutropenia lasting >3 days (no fever) and one failure to recover an absolute neutrophil count >1500/microl by day 35. This was, therefore, deemed the maximal tolerable dose. Number of treatment cycles per patient ranged between 1 and 6, and three patients completed six cycles. All patients were male, age 47-71, with NSCLC in one and SCLC in six. The patient with NSCLC had progressive disease after one cycle. One complete and three partial responses were observed in five patients with SCLC. Mean steady-state plasma concentrations during topotecan infusion ranged from 0.73 to 1.69 ng/ml, and mean etoposide concentrations ranged from 60 to 230 ng/ml. This sequence of topotecan, carboplatin, and etoposide appeared tolerable and active. Neutropenia was the dose-limiting toxicity.
Collapse
Affiliation(s)
- A A Miller
- Veterans Affairs Medical Center- Memphis, 1030 Jefferson Avenue, Memphis, TN 38104, USA.
| | | |
Collapse
|
20
|
Miller AA, Bernardoni R, Hindelang C, Kammerer M, Sorrentino S, Van de Bor V, Giangrande A. Role and mechanism of action of glial cell deficient/glial cell missing (glide/gcm), the fly glial promoting factor. Adv Exp Med Biol 2001; 468:33-46. [PMID: 10635018 DOI: 10.1007/978-1-4615-4685-6_4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Affiliation(s)
- A A Miller
- Institut de Génétique et de Biologie Moléculaire et Cellulaire IGBMC/CNRS/INSERM/ULP, Strasbourg, France
| | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
csrRS encodes a two-component regulatory system that represses the transcription of a number of virulence factors in Streptococcus pyogenes, including the hyaluronic acid capsule and pyrogenic exotoxin B. CsrRS-regulated virulence factors have diverse functions during pathogenesis and are differentially expressed throughout growth. This suggests that multiple signals induce CsrRS-mediated gene regulation, or that regulated genes respond differently to CsrR, or both. As a first step in dissecting the csrRS signal transduction pathway, we determined the mechanism by which CsrR mediates the repression of its target promoters. We found that phosphorylated CsrR binds directly to all but one of the promoters of its regulated genes, with different affinities. Phosphorylation of CsrR enhances both oligomerization and DNA binding. We defined the binding site of CsrR at each of the regulated promoters using DNase I and hydroxyl radical footprinting. Based on these results, we propose a model for differential regulation by CsrRS.
Collapse
Affiliation(s)
- A A Miller
- Department of Microbiology and Immunology, Unit for Laboratory Animal Medicine, 5641 Medical Science II, University of Michigan Medical School, Ann Arbor, MI 48109, USA
| | | | | |
Collapse
|
22
|
Niell HB, Perry MC, Clamon G, Crawford J, Miller AA, Herndon J, Green MR. Carboplatin/Etoposide/Paclitaxel in the Treatment of Patients with Extensive Small-Cell Lung Cancer. Clin Lung Cancer 2001; 2:204-9. [PMID: 14700479 DOI: 10.3816/clc.2001.n.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The purpose of this study was to examine the safety and efficacy of carboplatin/etoposide/paclitaxel in patients with untreated stage IV non-small-cell lung cancer (NSCLC) and extensive small-cell lung cancer (SCLC). Carboplatin was administered intravenously (i.v.) at an area under the curve (AUC) of 6 with etoposide at either 80 or 100 mg/m2 i.v. days 1-3 and paclitaxel at 175 or 200 mg/m2 i.v. over 3 hours along with 5 g/kg of granulocyte colony-stimulating factor subcutaneously on days 4-18, repeated every 3 weeks for 6 courses. Thirty-one patients (five NSCLC and 26 SCLC) entered into this phase I study. The median age was 63 (range, 42 to 74 years), with 24 males and seven females. The recommended dose level for phase II testing was carboplatin AUC = 6, etoposide 80 mg/m2 days 1-3, and paclitaxel 175 mg/m2 over 3 hours. With seven patients at this level, 14% had grade 4 neutropenia, 14% had grade 4 thrombocytopenia, none had grade 2/3 neurotoxicity, and no toxic deaths occurred. One of five (20%) patients with NSCLC responded, and 19 of 22 (86%) evaluable SCLC patients experienced a response to therapy. SCLC patients had a median survival of 10 months. The combination of carboplatin/etoposide/paclitaxel has significant activity with acceptable toxicity in patients with extensive SCLC.
Collapse
Affiliation(s)
- H B Niell
- Division of Hematology/Oncology, University of Tennessee, Memphis, Memphis, TN 38163, USA.
| | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
Different parasite species sharing the same intermediate host species may have similar or conflicting interests, depending on whether they are at the same stage in their life-cycle or whether they share the same definitive host. In the New Zealand cockle, Austrovenus stutchburyi, metacercariae of the digenean Meiogymnophallus sp. are positively associated with metacercariae of Curtuteria australis. This relationship is found in different cockle samples, and is independent of cockle shell size, which suggests that it is not merely the product of metacercariae accumulation over time. Both digenean species have the same definitive host, oystercatchers. Metacercariae of C. australis manipulate the phenotype of cockles, impairing the cockle's ability to burrow in the sediments. This makes the host more susceptible to oystercatcher predation. Thus Meiogymnophallus sp. can benefit by associating with C. australis and may hitch a ride with the manipulator parasite. This is supported by the finding that cockles impaired by C. australis and lying at the sediment surface harbour greater numbers of Meiogymnophallus than buried cockles. A third digenean species, whose sporocysts are found in cockles and which is not transmitted by predation, occurred only in surface cockles. Finally, a parasitic copepod with a direct life-cycle was found evenly distributed among buried and surface cockles, independently of their metacercarial loads. These results show that different parasite species do not use cockles in a random fashion, and that not all patterns of host use are consistent with shared or conflicting interests among parasites.
Collapse
Affiliation(s)
- R Poulin
- Department of Zoology, University of Otago, Dunedin, New Zealand.
| | | | | |
Collapse
|
24
|
Abstract
Maternal drug intake before delivery may influence the clinical behavior of the newborn. The effects of anesthetic agents and narcotics may cause symptoms of depression in the infant. Infants of substance-abusing mothers may also have altered clinical states. This is a case report of a newborn, very depressed at birth, who apparently was sedated by diphenhydramine (Benadryl) ingested by the mother before delivery. The importance of complete history of drug ingestion by mother before delivery is important in evaluating the behavior of a neonate.
Collapse
Affiliation(s)
- A A Miller
- Family Healthcare Medical Group, Thousand Oaks, CA 91361, USA.
| |
Collapse
|
25
|
Stronin OV, Miller AA, Podoplekina LE. [The characteristics of detecting the tick-borne encephalitis virus antigen in the ELISA and indirect hemagglutination reaction by means of scanning electron microscopy]. Zh Mikrobiol Epidemiol Immunobiol 1999:71-3. [PMID: 10851997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The surface of polystyrene plates was studied at different stages of the enzyme immunoassay (EIA) and the passive hemagglutination (PHA) test by the method of scanning electron microscopy in the detection of tick-borne encephalitis (TBE) virus antigen. The study revealed that in the process of EIA larger antigens were washed away from the plate surface. The objects detected on the polystyrene surface were identified as conglomerations of the virions of TBE virus, but whole virions were shown to play no decisive role in EIA. The conclusion was made that, due to some specific features of this method, EIA was more sensitive in reaction with small antigens (individual glycoproteids, their small complexes). And, respectively, the PHA test was more sensitive in reaction with large antigenic complexes (whole virions, their conglomerations, immune complexes).
Collapse
Affiliation(s)
- O V Stronin
- Research Institute of Vaccines and Sera, Research and Production Group Virion, Tomsk, Russia
| | | | | |
Collapse
|
26
|
Abstract
Fly gliogenesis depends on the glial-cell-deficient/glial-cell-missing (glide/gcm) transcription factor. glide/gcm expression is necessary and sufficient to induce the glial fate within and outside the nervous system, indicating that the activity of this gene must be tightly regulated. The current model is that glide/gcm activates the glial fate by inducing the expression of glial-specific genes that are required to maintain such a fate. Previous observations on the null glide/gcmN7-4 allele evoked the possibility that another role of glide/gcm might be to maintain and/or amplify its own expression. Here we show that glide/gcm does positively autoregulate in vitro and in vivo, and that the glide/gcmN7-4 protein is not able to do so. We thereby provide the first direct evidence of both a target and a regulator of glide/gcm. Our data also demonstrate that glide/gcm transcription is regulated at two distinct steps: initiation, which is glide/gcm-independent, and maintenance, which requires glide/gcm. Interestingly, we have found that autoregulation requires the activity of additional cell-specific cofactors. The present results suggest transcriptional autoregulation is a mechanism for glial fate induction.
Collapse
Affiliation(s)
- A A Miller
- Institut de Génétique et Biologie Moléculaire et Cellulaire, IGBMC/CNRS/INSERM/ULP, BP 163 67404 Illkirch, Communauté Urbaine de Strasbourg, France
| | | | | |
Collapse
|
27
|
Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol 1998; 16:3302-9. [PMID: 9779705 DOI: 10.1200/jco.1998.16.10.3302] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Preclinical and clinical data suggest that topotecan may be more effective, and perhaps less toxic, when administered as a continuous intravenous infusion (CIVI). A previous Cancer and Leukemia Group B (CALGB) trial of topotecan, given on a daily bolus schedule in combination with cisplatin, produced more hematologic toxicity than expected with either drug alone. Therefore, we designed this phase I trial to define the dose-limiting toxicities (DLTs) and the recommended phase II doses of cisplatin in combination with topotecan administered as a CIVI. Population pharmacodynamic models for the combination also were investigated. PATIENTS AND METHODS Patients with advanced solid tumors and a maximum of one prior chemotherapy regimen for metastatic disease were eligible if they had a performance status of 0 to 1 and adequate renal, hepatic, and bone marrow function. Prior treatment with camptothecins or platinum compounds and prior pelvic irradiation were not allowed. The initial schedule consisted of a fixed dose of topotecan 0.4 mg/m2/d administered as a CIVI for 21 days and escalating doses of cisplatin administered on days 1, 8, and 15 of a 28-day schedule, until the maximum tolerated dose (MTD) was achieved. After severe hematologic toxicity was observed in the first two patients, the topotecan infusion was shortened to 14 days, and the total dose of cisplatin was administered on day 1 in all subsequent patients. After the MTD was defined, that cohort was expanded to include a total of 12 assessable patients. Hematopoietic growth factors were not allowed. For the pharmacologic studies, total topotecan plasma concentrations were measured by high-pressure liquid chromatography (HPLC) during infusion on days 3, 8, and 11 on the first cycle, and the median steady-state concentration (Tss) was determined. Platinum plasma concentrations on day 3 were measured by atomic absorption spectrometry. RESULTS Of the 32 patients enrolled, 28 were assessable for toxicity and 24 for response. The primary toxicity was hematologic, with both neutropenia and thrombocytopenia being dose-limiting. The MTD of cisplatin was 75 mg/m2 on day 1 in combination with topotecan 0.4 mg/m2/d for 14 days. At this dose level, three of a total of 12 assessable patients had DLT. The pharmacodynamic relationship between Tss and the absolute neutrophil count at the nadir (ANCn) was described by the following equation: log10 (ANCn)=4.23 - 0.47 x Tss - 0.01 x cisplatin dose (P < .0001; R2=0.64). The substitution of platinum concentration for cisplatin dose in this model did not result in a significant improvement. Three patients had a partial response: one with duodenal carcinoma; a second with small-cell lung cancer; and a third with melanoma. CONCLUSION Cisplatin can be given safely in combination with CIVI topotecan. However, toxicity was still substantial. Based on the current results and our previous trial of this combination, we conclude that, when combined with cisplatin, CIVI topotecan does not seem to be advantageous compared with the more traditional daily bolus schedule.
Collapse
Affiliation(s)
- R C Lilenbaum
- Mt. Sinai Comprehensive Cancer Center, Miami Beach, FL 33140, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
Glial cells differentiate from the neuroepithelium. In flies, gliogenesis depends on the expression of glial cell deficient/glial cell missing (glide/gcm). The phenotype of glide/gcm loss- and gain-of-function mutations suggested that gliogenesis occurs in cells that, by default, would differentiate into neurons. Here we show that glide/gcm is able to induce cells even from a distinct germ layer, the mesoderm, to activate the glial developmental program, which demonstrates that gliogenesis does not require a ground neural state. These findings challenge the common view on the establishment of cell diversity in the nervous system. Strikingly, ectopic glide/gcm overrides positional information by repressing the endogenous developmental program. These findings also indicate that glial differentiation tightly depends on glide/gcm transcriptional regulation. It is likely that glide/gcm homologs act similarly during vertebrate gliogenesis.
Collapse
Affiliation(s)
- R Bernardoni
- Institut de Génétique et Biologie Moléculaire et Cellulaire, IGBMC/CNRS/ULP-BP 163 67404 Illkirch, c.u. de Strasbourg, France
| | | | | |
Collapse
|
29
|
Miller AA, Tolley EA, Niell HB. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer. Clin Cancer Res 1998; 4:1705-10. [PMID: 9676845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The purpose of this study was to prospectively test a pharmacodynamic model for therapeutic drug monitoring of 21-day oral etoposide. In our previous studies, etoposide trough concentrations on this schedule were related to the hematological toxicity, expressed as WBC and neutrophil counts at the nadir. The following pharmacodynamic model estimated the absolute neutrophil count at the nadir (ANCn) based on the etoposide concentration (Ec) and the pretreatment count (ANCp): ANCn=0.32(1 + ANCp x e(-2.47 x Ec)). Patients were treated with 40 mg/m2/day etoposide p.o. x 21 days and 100 mg/m2 cisplatin i.v. on day 1. All patients had non-small cell lung cancer stage IIIB or IV, had a performance status of 0-2, and had a median age of 66 (range, 42-80). Etoposide was measured in the plasma on day 8 by high-performance liquid chromatography, and dosage adjustments were made for the remainder of the course. We targeted for grade 3 neutropenia (ANCn, 500 to 999/microl) and attempted to avoid grade 4 neutropenia (ANCn, <500/microl). Of 25 patients entered, 22 were evaluable for therapeutic drug monitoring in the first course. Three patients developed grade 3 neutropenia, and seven patients developed grade 4 neutropenia. Etoposide concentrations were significantly correlated with ANCn in the first course (r=-0.50, P < 0.02). For those patients whose dosages were not changed, the estimated correlation between predicted and actual ANCn was 0.77 (P < 0.01). No evidence of significant bias of the pharmacodynamic model was detected. The etoposide dosages were increased in 12 patients and were not changed in the remaining patients. The precision of the model was good in patients whose dosages were not changed but poor in patients whose dosages were increased. The actual observed ANCn was compared with the predicted ANCn based on the pharmacodynamic model. The prediction was considered accurate if the predicted and actual ANCn values were within 500/microl of each other. Using this margin, the ANCn was accurately predicted in 10 of 22 patients. Etoposide concentrations >0.3 microg/ml on this schedule were significantly correlated with combined grades 3 and 4 neutropenia (P < 0.0001). In conclusion, the pharmacodynamic model is statistically sound when applied to a population of patients. However, when applied to individual patients for therapeutic drug monitoring, the model lacks precision and accuracy.
Collapse
Affiliation(s)
- A A Miller
- Department of Veteran Affairs Medical Center, University of Tennessee, Memphis 38163, USA.
| | | | | |
Collapse
|
30
|
Kolosova MV, Novitskiĭ VV, Kravets EB, Filippov GP, Stepovaia EA, Mikhalenko AN, Miller AA, Tarkhova EP, Dorovskikh IA, Batukhtin AV, Kalinina LV. [Features of surface architectonics and ultrastructure of peripheral blood in children with insulin-dependent diabetes mellitus]. Klin Lab Diagn 1997:16-8. [PMID: 9377016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Electron microscopic study of the surface architectonics and ultrastructure of the peripheral blood erythrocytes in 25 children with insulin-dependent diabetes mellitus (IDDM) revealed that the decrease of the count of disk-shaped cells, increased count of transitional and degenerative forms, and alteration of their ultrastructure. Traditional therapy failed to completely normalized these characteristics over the entire follow-up.
Collapse
|
31
|
Neill HB, Miller AA, Clamon GH, Perry MC, Crawford J, Green MR. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Semin Oncol 1997; 24:S12-130-S12-134. [PMID: 9331137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We initiated a phase II pilot study to determine whether adding paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to combination carboplatin/etoposide is tolerable and active in patients with advanced non-small cell lung cancer and extensive small cell lung cancer. Patients were given carboplatin (area under the concentration-time curve of 6) followed by etoposide 80 to 100 mg/m2 intravenously on days 1 through 3 followed by paclitaxel 200 mg/m2 intravenously over 3 hours on day 3. On days 4 through 18, granulocyte colony-stimulating factor 5 microg/kg was administered subcutaneously. Each cycle was repeated every 21 days. Fourteen patients have been accrued to the study and 12 were evaluated for toxicity, the first 10 of whom were treated with 80 mg/m2 etoposide. Among the first 10 evaluable patients, significant grade 4 neutropenia occurred in one patient, grade 4 thrombocytopenia in three patients, grade 2 neuropathy in two patients, and grade 3 neurotoxicity in two patients. None of the four patients with non-small cell lung cancer responded to treatment, while six of seven small cell lung cancer patients have obtained major responses to therapy. We have increased the etoposide dose to 100 mg/m2 in subsequent patients. The combination chemotherapy regimen of carboplatin, etoposide, and paclitaxel is tolerable and active in patients with small cell lung cancer.
Collapse
Affiliation(s)
- H B Neill
- University of Tennessee-Memphis, 38163, USA
| | | | | | | | | | | |
Collapse
|
32
|
Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res 1997; 3:719-25. [PMID: 9815741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
This was a pharmacological companion study to a randomized Phase III trial comparing 21-day oral versus 3-day i.v. etoposide in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer. Etoposide plasma concentrations were measured in patients randomized to the 21-day schedule and correlated with toxicity and tumor response. Patients were treated with etoposide (50 mg/m2/day) orally for 21 days and cisplatin (33 mg/m2/day) i.v. for 3 consecutive days every 28 days for 6 courses. Plasma samples before the daily etoposide dose (trough concentrations) and complete blood counts were obtained weekly during treatment. The average of three etoposide concentrations (EC) per course was calculated. Of 158 patients registered to this schedule of the study, 150 were eligible. In 106 patients, etoposide samples were obtained at least in the first course in which the mean EC was 0.39 microgram/ml (SD = 0.29). In 102 patients (missing albumin values in 4 of 106 patients), the concentration of etoposide not bound to protein (Efree) was estimated based on the following equation: percentage unbound = (1.4 x total bilirubin) - (6.8 x albumin) + 34.4. Regression analysis revealed that increasing age was correlated with higher EC (r = 0.27; two-tailed P < 0.01) and Efree (r = 0.31; two-tailed P < 0.01). Higher EC and Efree values were associated with lower WBC counts and absolute neutrophil counts after the first treatment course in 83 patients with nadir counts. Using multiple linear regression, a pharmacodynamic model was developed that included EC or Efree, age, and alkaline phosphatase. An interaction with bone marrow results at diagnosis was found, indicating a sharper decline in nadir counts with increasing EC or Efree when the marrow was involved with small cell lung cancer. This model explained 29% of the variation for WBC nadirs (P < 0.001) and 31% of the variation for absolute neutrophil count nadirs (P < 0. 001). Neither EC nor Efree showed a significant correlation with tumor response. A pharmacokinetic relationship between EC or Efree and age was found. A pharmacodynamic model could be developed for toxicity but not for tumor response.
Collapse
Affiliation(s)
- A A Miller
- University of Tennessee, Memphis, Tennessee 38163, USA.
| | | | | | | | | | | |
Collapse
|
33
|
Robert F, Molthrop DC, Miller AA, Lee BC, Chen S, Wheeler RH. Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer. Am J Clin Oncol 1996; 19:483-6. [PMID: 8823476 DOI: 10.1097/00000421-199610000-00011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We assessed the efficacy and toxicity of two etoposide infusional schedules in patients with advanced non-small cell lung cancer (NSCLC). Twenty-six patients were treated with a 21-day infusion every 28 days at a dose of 25-40 mg/m2/d, and six patients with a 7-day infusion every 21 days at a dose of 45-75 mg/m2/d. Sixty-three percent of patients had a Karnofsky status of 80% or better, and only five (15%) patients had prior chemotherapy. Plasma etoposide concentrations were determined in 26 patients. Sixty-nine treatment cycles were administered. Two patients (6.3%; 90% confidence interval, 1.1-18.4%) had partial responses; with response durations of 2 and 7 months, respectively. The median survival was 4 months. Grade 3 or 4 neutropenia occurred in 13 of 69 cycles (19%) and was associated with three toxic deaths. Ten patients required RBC transfusions. Nausea was common, but was associated with vomiting in only 7% of all cycles. The interpatient variability of etoposide concentrations at steady state was significant. We conclude that the antitumor activity of prolonged infusion of etoposide is not superior to standard dose and schedule in advanced NSCLC.
Collapse
Affiliation(s)
- F Robert
- Birmingham Veteran's Administration Medical Center, Alabama, USA
| | | | | | | | | | | |
Collapse
|
34
|
Abstract
BACKGROUND Fadrozole hydrochloride (CGS-16949A) belongs to the class of aromatase inhibitors that lowers circulating estrogen levels by inhibiting the conversion of androgens to estrogens, thereby causing tumor regression in patients with breast carcinoma. METHODS This was a prospective, randomized, Phase II study of fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. The three treatment groups received, respectively, fadrozole hydrochloride 0.6 mg three times daily, 1 mg twice daily, and 2 mg twice daily orally. RESULTS Fifty-six patients were entered on protocol and 54 were eligible (2 patients were perimenopausal). Eight patients had received no prior therapy, 15 patients had received prior hormonal therapy, 5 patients had received prior chemotherapy, and 28 patients had received both. After 12 weeks of treatment, 2 complete and 3 partial responses were observed. Forty patients continued treatment beyond 12 weeks, and 3 additional responses were achieved. Thus, 8 of 56 patients responded (14% overall response rate). Responses did not appear to be dose-related. The median duration of response was 36 months (range, 8-45 months). Subjective toxicity was mild to moderate and appeared more frequent on the 2 mg twice daily dosing schedule. No objective toxicity in laboratory parameters was observed. No patient had severe or life-threatening toxicity. Fadrozole hydrochloride plasma concentrations (obtained every 2 weeks for 12 weeks) appeared to be dose-dependent and noncumulative. CONCLUSIONS This study confirms modest activity of fadrozole hydrochloride in a heterogeneous group of patients with breast carcinoma treated at three different dose levels.
Collapse
Affiliation(s)
- A A Miller
- Department of Medicine, University of Tennessee, Memphis 38163, USA
| | | | | | | | | | | |
Collapse
|
35
|
Robert F, Chen S, Miller AA, Lee BC, Molthrop DC, Wheeler RH. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer. Cancer Chemother Pharmacol 1996; 38:459-65. [PMID: 8765440 DOI: 10.1007/s002800050511] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
PURPOSE This phase I study was undertaken to evaluate the safety and tolerability of prolonged infusional etoposide, and to evaluate its pharmacokinetic/pharmacodynamic profile in patients with advanced cancer. METHODS A group of 17 patients received a 7-day infusion of etoposide (schedule A) every 21 days at doses from 30 to 75 mg/m2 per day, and a second group of 37 patients a 21-day infusion (schedule B) every 28 days at doses from 18 to 40 mg/m2 per day. Patients had a median Karnofsky performance status (PS) of 80%, and 34 patients had no prior chemotherapy. Etoposide concentrations at steady state (Css) and other pharmacokinetic parameters (plasma clearance, CLp; area under the curve, AUC) were determined during the first treatment cycle. Correlation coefficients were calculated to measure the relationship between variables. RESULTS Myelosuppression was the major toxicity, and was associated with three deaths. The maximum tolerated dose due to neutropenia was 75 mg/m2 per day for schedule A and 40 mg/m2 per day for schedule B. There was significant interpatient pharmacokinetic variability in both infusional schedules. Even though etoposide dose levels did not significantly correlate with plasma levels, the Css was > or = 1 microgram/ml in the majority of the patients. A significant correlation between AUC and neutrophil absolute decrease was noted only in schedule B (r = 0.56, P = 0.003). There were several marginal relationships in schedule B: PS versus Css (r = 0.31, P = 0.058), PS versus AUC (r = -0.38; P = 0.058) and age versus CLp (r = -0.31, P = 0.057). CONCLUSION Overall, significant correlations were found for several hematologic variables and etoposide dose levels, but not with the Css values. One major problem with the application of pharmacodynamic models to predict hematologic toxicity in clinical practice is the presence of significant interpatient variability.
Collapse
Affiliation(s)
- F Robert
- Comprehensive Cancer Center, University of Alabama at Birmingham 35294-3300, USA
| | | | | | | | | | | |
Collapse
|
36
|
Miller AA, Lilenbaum RC, Lynch TJ, Rosner GL, Ratain MJ, Green MR, Schilsky RL. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 1996; 14:1964-5. [PMID: 8656268 DOI: 10.1200/jco.1996.14.6.1964] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
|
37
|
Abstract
Radiation oncology registrar training varies between centres, reflecting to some extent the varied training experiences of specialists. The attempts of one department to formalize the philosophy, aims and structure of its training are described and illustrated.
Collapse
Affiliation(s)
- A A Miller
- Department of Radiotherapy and Clinical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
| | | |
Collapse
|
38
|
Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol 1995; 13:2230-7. [PMID: 7545219 DOI: 10.1200/jco.1995.13.9.2230] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
PURPOSE To define the dose-limiting toxicities (DLTs) and the recommended phase II doses of paclitaxel combined with topotecan, without and with filgrastim support. PATIENTS AND METHODS Patients with advanced solid tumors and a maximum of one prior chemotherapy regimen for metastatic disease were eligible if they had a performance status of 0 to 1 and normal renal, hepatic, and bone marrow function. Prior treatment with taxanes or comptothecin analogs, and prior pelvic irradiation were not allowed. Patients with a history of cardiac disease or on medications known to affect cardiac conduction were excluded. The dose of topotecan was fixed at 1.0 mg/m2/d for 5 days. The dose of paclitaxel was escalated until the maximum-tolerated dose (MTD), without and with filgrastim 5 micrograms/kg subcutaneously (SC) on days 6 to 14, was reached. Paclitaxel was administered over 3 hours on day 1 before topotecan. Treatment cycles were repeated every 21 days. RESULTS Of 46 patients entered, 45 were assessable for toxicity and 34 for response. The principal toxicity was neutropenia. Without filgrastim, the MTD of paclitaxel was 80 mg/m2 on day 1 in combination with topotecan 1.0 mg/m2/d for 5 days. With filgrastim, the dose of paclitaxel was escalated to 230 mg/m2 in combination with the same dose of topotecan. At this dose level, one patient had hematologic DLT and a second patient developed neuromuscular DLT. Three patients had a partial response (PR): one with head and neck cancer, a second with non-small-cell lung cancer, and the third with colon cancer. CONCLUSION We conclude that paclitaxel can be given at clinically relevant doses in combination with topotecan and filgrastim. The recommended dose for phase II studies is paclitaxel 230 mg/m2 on day 1 and topotecan 1.0 mg/m2/day for 5 days with filgrastim 5 micrograms/kg on days 6 to 14.
Collapse
|
39
|
Miller AA, Herndon JE, Hollis DR, Ellerton J, Langleben A, Richards F, Green MR. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995; 13:1871-9. [PMID: 7636529 DOI: 10.1200/jco.1995.13.8.1871] [Citation(s) in RCA: 83] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PURPOSE This was a randomized phase III study to test the schedule dependency of etoposide given as a conventional 3-day intravenous (IV) regimen versus a prolonged 21-day oral regimen for extensive-stage small-cell lung cancer (SCLC). Both regimens contained IV cisplatin. The objectives were to compare survival (primary end point) and to establish response rates, failure-free survival, and toxicity (secondary end points). PATIENTS AND METHODS Patients with untreated measurable or assessable disease and normal organ function were eligible. Randomization was stratified according to performance status 0 versus 1 or 2. Treatment consisted of etoposide 130 mg/m2/d IV for 3 days and cisplatin 25 mg/m2/d IV for 3 days every 21 days for eight courses (schedule 1) versus etoposide 50 mg/m2/d orally for 21 days and cisplatin 33 mg/m2/d IV for 3 days every 28 days for six courses (schedule 2). In 1990, bioavailability of oral etoposide was assumed to be 50%, and the study was designed to deliver the same total doses of etoposide and cisplatin on both regimens over 24 weeks without the use of growth factors. RESULTS Between December 1990 and October 1993, 306 eligible patients were entered. Of these, 69% were male and 66% were > or = 60 years of age; 21% had a performance status of 0, 47% a performance status of 1, and 32% a performance status of 2; 156 were randomized to receive schedule 1 and 150 to receive schedule 2. Overall median survival estimates were 9.5 and 9.9 months (difference not significant) for schedule 1 and schedule 2, respectively. The 95% confidence interval (CI) for overall survival, 8 to 11 months, was the same for both schedules, with 126 and 117 deaths on schedule 1 and 2, respectively. Both schedules also resulted in the same median failure-free survival estimate of 7 months (95% CI, 6 to 8 months on either schedule). Complete and partial responses were observed in 15% and 42% of patients on schedule 1 and 14% and 47% on schedule 2, respectively. The overall maximal hematologic toxicities grade 3 and 4 for leukocytes, neutrophils, platelets, and hemoglobin were, respectively, as follows: schedule 1, 62%, 85%, 32%, and 32%; schedule 2, 83%, 83%, 52%, and 53%. Lethal toxicity due to neutropenia and infection occurred in 4% of patients on schedule 1 and 10% on schedule 2 (difference not statistically significant). CONCLUSION The two schedules of etoposide in combination with cisplatin did not result in differences in treatment outcome with respect to tumor response and survival. However, a significantly greater rate of severe or life-threatening hematologic toxicity was noted on the 21-day oral etoposide treatment schedule.
Collapse
Affiliation(s)
- A A Miller
- University of Tennessee, Memphis 38163, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Thompson DS, Greco A, Miller AA, Srinivas NR, Igwenezue KB, Hainsworth JD, Schacter LP, Kaul S, Barbhaiya RH, Garrow C. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clin Pharmacol Ther 1995; 57:499-507. [PMID: 7768072 DOI: 10.1016/0009-9236(95)90034-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
PURPOSE To determine the maximum tolerated dose, toxicities, kinetics, and disposition of etoposide phosphate when administered as a daily 30-minute infusion for 5 days. PATIENTS AND METHODS Twenty-eight patients were enrolled in this phase I dose-escalation trial. Cohorts of patients received etoposide phosphate in etoposide equivalent doses of 50, 75, 100 and 125 mg/m2 intravenously for 30 minutes each day for 5 days. Pharmacokinetic sampling of both blood and urine was performed and concentrations of etoposide and etoposide phosphate were determined on day 1 of study for each patient and on day 4 of study for three patients receiving the 100 mg/m2 dose. RESULTS The dose-limiting toxicity was reversible myelosuppression as evidenced by leukopenia and neutropenia. Toxicities seen were comparable to those expected from etoposide administration. With this schedule, the 100 mg/m2 dose was the maximum tolerated dose. Nonhematologic toxicities were generally mild. Two patients had major responses and three others had minor responses. Pharmacokinetic analyses revealed rapid (< 15 minutes) extensive conversion of etoposide phosphate to etoposide. Peak plasma etoposide concentrations and etoposide areas under the curve were proportional to the dose of etoposide phosphate administered. Etoposide kinetics were similar to those expected after a comparable dose of etoposide. CONCLUSIONS Etoposide phosphate is a water-soluble pro-drug of etoposide that is rapidly converted to etoposide in vivo with a toxicity profile similar to etoposide. Etoposide generated from etoposide phosphate exhibits linear kinetics over a dose range of 50 to 125 mg/m2. When administered as a daily 30-minute infusion for 5 days, the dose-limiting toxicity is myelosuppression and 100 mg/m2 daily is the maximum tolerated dose.
Collapse
Affiliation(s)
- D S Thompson
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Miller AA, Hamilton CS, Reid AL, Ireland MC. Delays in diagnosis of head and neck cancer. Med J Aust 1995; 162:334. [PMID: 7715505 DOI: 10.5694/j.1326-5377.1995.tb139923.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
42
|
Miller AA, Niell HB, Griffin JP. Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer. Lung Cancer 1995; 12:59-65. [PMID: 7600031 DOI: 10.1016/0169-5002(94)00406-d] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The objectives of the study were to evaluate the combination of cisplatin and prolonged oral etoposide for response rate, survival, and toxicity. The treatment regimen consisted of etoposide (50 mg/m2/day) p.o. for 21 consecutive days and cisplatin (100 mg/m2) i.v. on day 1 every 28 days for up to six courses. Patients with Stage IIIB or IV non-small cell lung cancer who had not received prior chemotherapy and had an ECOG performance status of 0-2 were eligible if they had normal bone marrow, liver and renal functions. Patients were followed weekly for toxicity including complete blood counts. The total number of patients entered in the study was 60, of whom 56 were male and four female, 40 white and 20 African Americans. Median age was 64 years (range, 39-77). Performance status 0, 1, and 2 was present in five, 39, and 16 patients, respectively. Fourteen patients had Stage IIIB and 46 Stage IV disease. A total of 142 treatment courses were administered (median 2, range 1-6). Three patients had a complete response and 19 patients had a partial response for an objective response rate of 37% (95% confidence interval, 31-43%). Median survival was 5 months (range, 1-39+). Neutropenia was the major toxicity with Grade 4 occurring in 25 patients after the first course. The following percent of patients experienced severe or life-threatening hematologic toxicity (Grade 3 and 4 combined) over all courses: leukopenia, 73%; neutropenia, 73%; anemia, 42%; and thrombocytopenia, 37%. Three patients died of neutropenic sepsis.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A A Miller
- Veterans Affairs Medical Center, Memphis, TN, USA
| | | | | |
Collapse
|
43
|
Abstract
The objective of this clinical and pharmacological study was to determine whether any pretreatment parameters were associated with pharmacological or toxicity parameters after prolonged oral etoposide. Therefore, the relationships between patient characteristics and etoposide concentrations and hematological toxicity were evaluated. Sixty patients with advanced non-small cell lung cancer were treated with etoposide 50 mg/m2/day p.o. for 21 consecutive days and cisplatin 100 mg/m2 i.v. on day 1. Complete blood counts and etoposide plasma concentrations were obtained weekly. Etoposide was measured by high-performance liquid chromatography. The input variables were age, gender, race, weight, weight0.66, weight0.75, height, body surface area, performance status, albumin concentration; and total etoposide dose. The outcome measures were etoposide concentration; nadir values (white blood cells, neutrophils, hemoglobin, and platelets); the absolute decrease, relative decrease, and survival fraction of blood cells; and graded toxicity. No significant correlations were found in 49 fully evaluable patients between any of the input and outcome variables. Among the outcome variables, significant correlations were found between etoposide concentration and the logarithmic transformation of the nadir blood counts. If any of the input variables were significantly correlated to etoposide concentrations or toxicity variables, it would be possible to suggest another predictor variable besides body surface area. As long as treatment is not modified for etoposide concentrations, dosing of oral etoposide must still rely on estimates of body surface area.
Collapse
Affiliation(s)
- A A Miller
- Veterans Affairs Medical Center, Division of Hematology and Medical Oncology, Memphis, Tennessee, USA
| | | | | |
Collapse
|
44
|
Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol 1994; 12:2743-50. [PMID: 7527456 DOI: 10.1200/jco.1994.12.12.2743] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
PURPOSE The objectives of this phase I trial were to determine the dose-limiting toxicities (DLTs) of the novel topoisomerase I inhibitor topotecan combined with cisplatin, to define the maximum-tolerated doses (MTDs) of the combination without and with the use of filgrastim, and to define recommended doses for phase II trials. PATIENTS AND METHODS Patients with advanced solid tumors were eligible if they had normal bone marrow, renal, and hepatic function and had not previously been treated with platinum compounds. Topotecan was administered intravenously on days 1 through 5 and cisplatin was administered intravenously on day 1 of a 21-day cycle. The topotecan dose was fixed at 1.0 mg/m2/d on the first four dose levels, and cisplatin was escalated in 25-mg/m2 increments from 25 to 100 mg/m2 without filgrastim. After encountering DLT, the dose of cisplatin was decreased by one level and topotecan dose escalation was attempted. After defining the MTD without growth factor, the study proceeded with escalating cisplatin doses to define the MTD with filgrastim 5 micrograms/kg subcutaneously (SC) daily starting on day 6 of treatment. Priming with filgrastim 5 micrograms/kg SC on days -6 to -2 before the first course was explored last. RESULTS Of 38 patients entered, 37 were eligible, 35 assessable for toxicity in the first course, and 28 assessable for response. The principal toxicity was grade 4 neutropenia, which had to last more than 7 days to be considered dose-limiting. No DLT was observed at the starting cisplatin dose of 25 mg/m2 (dose level 1). On level 2 (cisplatin 50 mg/m2, one patient had dose-limiting neutropenia and one patient had grade 3 renal toxicity. On level 3 (cisplatin 75 mg/m2), two patients had dose-limiting neutropenia. Therefore, cisplatin dose escalation was stopped. On dose level 5 (cisplatin 50 mg/m2 and topotecan 1.25 mg/m2/d), one patient had grade 4 neutropenia that lasted more than 7 days and one patient died of neutropenic sepsis. The remaining dose levels used topotecan 1.0 mg/m2/d plus cisplatin 75 mg/m2 (level 6) and 100 mg/m2 (levels 7 and 8) with filgrastim. No DLT was observed on level 6. On level 7, two patients had dose-limiting neutropenia and one patient had grade 3 hyperbilirubinemia. Priming with filgrastim on level 8 demonstrated no obvious advantage over level 7, and one patient had grade 4 thrombocytopenia that lasted more than 7 days. Three patients with non-small-cell lung cancer achieved a partial response and one patient with breast cancer had a complete response. CONCLUSION Topotecan and cisplatin in combination cause more neutropenia than expected from either drug given alone at the same dosage. The recommended phase II doses are topotecan 1.0 mg/m2/d for 5 days in combination with cisplatin 50 mg/m2 on day 1 without filgrastim or cisplatin 75 mg/m2 on day 1 with filgrastim support.
Collapse
|
45
|
Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 1994; 74:2949-55. [PMID: 7525038 DOI: 10.1002/1097-0142(19941201)74:11<2949::aid-cncr2820741110>3.0.co;2-q] [Citation(s) in RCA: 86] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND Treatment of the symptoms of bone metastases currently involves the use of narcotic medication, radiation therapy, or hormonal therapy. Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial. METHODS Ambulatory female patients age 18 years or older with breast cancer metastatic to bone and a life expectancy of at least 3 months were eligible for the study. Bone metastases were confirmed by bone scan or bone survey within 6 months of enrollment. Sixty-one patients were treated as outpatients and were randomized to receive one of four intravenous pamidronate regimens for 12 weeks: 30 mg administered every 2 weeks, 60 mg every 4 weeks, 60 mg every 2 weeks, or 90 mg every 4 weeks. The primary efficacy parameter for this study was pain score. The change from baseline in pain score was determined for each patient at each study visit and at endpoint, defined as the last postbaseline evaluation for each patient before or at week 12. Secondary efficacy variables included narcotic scores, urinary calcium/creatinine and hydroxyproline/creatinine ratios, serum osteocalcin and bone alkaline phosphatase concentrations, and bone lesion (radiologic) response. RESULTS At 3 months, the regimens of 60 mg every 4 weeks, 60 mg every 2 weeks, and 90 mg every 4 weeks resulted in significant reduction in bone pain beginning by week 6 of treatment. The regimen of 30 mg every 2 weeks was not effective. Narcotic use, as reflected by narcotic scores, did not parallel the pain scores, because there was little evidence of any effect for any of the treatment groups. Reduction in bone pain was accompanied by decreases in urinary calcium/creatinine and hydroxyproline/creatinine ratios, and bone alkaline phosphatase concentrations. Side effects of pamidronate were mild and transient. Radiographic changes consistent with healing of lytic lesions were observed in 15 patients (25%). CONCLUSION Intravenous pamidronate is a well tolerated treatment that produced significant relief of bone pain in the majority of patients with metastatic breast cancer at the three highest doses tested.
Collapse
Affiliation(s)
- D Glover
- Presbyterian University Hospital, Philadelphia, Pennsylvania
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Miller AA, Tolley EA. Predictive performance of a pharmacodynamic model for oral etoposide. Cancer Res 1994; 54:2080-3. [PMID: 8174108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The objective of this work was to prospectively validate a pharmacodynamic model for 21-day oral etoposide. The model had been developed in 27 untreated patients with stage IIIB or IV non-small cell lung cancer. Treatment consisted of 50 mg/m2/day, p.o., etoposide for 21 days in combination with 100 mg/m2, i.v., cisplatin on day 1 every 28 days for up to 6 courses. Weekly evaluations included etoposide plasma concentrations (Ec, microgram/ml) before the daily dose and WBC and neutrophil counts (ANC, 10(3)/microliters). The relationship between Ec and the pretreatment (WBCp, ANCp) and nadir counts (WBCn, ANCn) in the first course was described as follows: WBCn = 0.35 (1 + WBCp x e-1.12 x Ec)) ANCn = 0.32 (1 + ANCp x e-2.47 x Ec) The same study criteria were used to enter 26 additional patients, and 21 were evaluable for pharmacodynamics (5 had incomplete data). Predicted nadir counts were not significantly different from observed nadir counts (paired t test, P > 0.4). There were 12 and 7 patients correctly predicted to be above and below, respectively, the clinically important ANCn of 0.5 x 10(3)/microliters. The model performed reliably, and therapeutic drug monitoring appears warranted in future studies.
Collapse
Affiliation(s)
- A A Miller
- Veterans Affairs Medical Center, Memphis, Tennessee
| | | |
Collapse
|
47
|
Affiliation(s)
- A A Miller
- Department of Medicine, University of Tennessee, Memphis 38163
| | | |
Collapse
|
48
|
Alvarado M, Bass HN, Caldwell S, Jamehdor M, Miller AA, Jacob P. Miller-Dieker syndrome. Detection of a cryptic chromosome translocation using in situ hybridization in a family with multiple affected offspring. Am J Dis Child 1993; 147:1291-4. [PMID: 8249946 DOI: 10.1001/archpedi.1993.02160360033012] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
OBJECTIVE To describe a family in whom fluorescence in situ hybridization allowed for accurate diagnosis of Miller-Dieker syndrome in an at-risk pregnancy and determination of parental carrier status. DESIGN Retrospective case analysis and application of a new molecular tool to evaluate the family. SETTING Health maintenance organization. The family was followed up by the Departments of Medical Genetics, Pediatrics, and Obstetrics and Gynecology, Kaiser Permanente Medical Center, Panorama City, Calif. PARTICIPANTS Members of a single family. INTERVENTIONS Clinical evaluation and neuroimaging studies of the proband. Prenatal diagnosis via ultrasonography and amniocentesis. Chromosomal evaluation of the couple and their offspring. In situ hybridization studies in both parents and an affected fetus. MEASUREMENTS/MAIN RESULTS We describe a family in whom fluorescence in situ hybridization detected a submicroscopic deletion of the Miller-Dieker syndrome critical region 17p13.3 arising from a cryptic translocation in one of the parents. The proband was determined at birth owing to the presence of multiple congenital anomalies, including low birth weight, microcephaly, agenesis of the corpus callosum, lissencephaly, cerebral atrophy, unilateral ptosis, polydactyly, and omphalocele. High-resolution chromosome-banding analysis findings were normal in the parents and proband, who died at age 4 years. There were four subsequent pregnancies: two ended in first-trimester spontaneous abortion, and in the other two, large omphaloceles were detected in fetuses at 15 and 13 weeks' gestation. Both pregnancies were terminated. Fluorescence in situ hybridization probes for 17p13.3 had become available before the most recent pregnancy and were used to study parental and fetal cells. As a result, a balanced cryptic translocation between chromosome 17 and chromosome 19 was identified in the father: 46,XY,t(17;19)(p13.3q13.33). An unbalanced form of the translocation, involving a deletion of 17p13.3, was detected with fluorescence in situ hybridization in the fetus. This finding was in accordance with a clinical diagnosis of Miller-Dieker syndrome. CONCLUSIONS Molecular cytogenetic technology should be used in cases of suspected Miller-Dieker syndrome when high-resolution cytogenetic analysis fails to detect del(17) (p13.3). Positive findings should be followed up with parental studies. In addition, omphalocele should be included among the list of malformations that make up the Miller-Dieker syndrome.
Collapse
Affiliation(s)
- M Alvarado
- Department of Medical Genetics, Kaiser Permanente Medical Center, Panorama City, CA 91402-5497
| | | | | | | | | | | |
Collapse
|
49
|
Abstract
Our aim was to determine the role of fetal breathing movements (FBM) in the maintenance of fetal lung liquid volume. Experiments were performed in 14 chronically catheterized fetal sheep. FBM were selectively abolished for 48 h by the infusion of tetrodotoxin (TTX) onto the phrenic nerves of five fetuses. Lung liquid volumes and secretion rates were measured before each treatment, 46-48 h after the start of the TTX infusion, and 22-24 h after the end of the infusion. Blockade of the phrenic nerves reduced fetal lung liquid volumes from 27.6 +/- 1.9 to 21.8 +/- 2.6 ml/kg and increased lung liquid secretion rates from 3.8 +/- 0.6 to 6.2 +/- 1.1 ml.h-1.kg-1. Control experiments confirmed the lack of effect of TTX infused intravenously and saline infused intrapleurally on changes in fetal lung liquid volume and secretion rate. To measure the static relaxation volume of the fetal lung, in six fetuses we combined skeletal muscle paralysis with bypass of the upper airway for 48 h. This reduced fetal lung liquid volume from 39.1 +/- 3.1 to 23.0 +/- 2.5 ml/kg and increased lung liquid secretion rates from 4.1 +/- 0.7 to 5.8 +/- 0.9 ml.h-1.kg-1. This experiment demonstrates that the fetal lung is normally maintained at a level of expansion that is much greater than its static relaxation volume. We conclude that the volume of luminal liquid in the fetal lungs is dependent on the diaphragmatic contractions associated with FBM. Their effect is to resist the elastic recoil of the fetal lungs, thereby reducing the loss of liquid from the lungs via the trachea.
Collapse
Affiliation(s)
- A A Miller
- Department of Physiology, Monash University, Clayton, Victoria, Australia
| | | | | |
Collapse
|
50
|
Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1993; 11:1179-88. [PMID: 8388920 DOI: 10.1200/jco.1993.11.6.1179] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
PURPOSE This study was undertaken to investigate the pharmacodynamic relationship between etoposide drug levels on 21-day oral treatment courses and hematologic toxicities in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Thirty-two patients with stage IIIB or IV NSCLC were treated with oral etoposide 50 mg/m2/d for 21 consecutive days in combination with cisplatin 100 mg/m2 on day 1. Treatment was repeated every 28 days for up to six courses. Patients had not received previous chemotherapy and had a performance status of 0 to 2. Patients were monitored weekly while on treatment for compliance with oral etoposide and toxicity, including complete blood cell counts, and a blood sample before the daily etoposide dose (drug trough levels). Etoposide concentrations were measured in the plasma by high-performance liquid chromatography (HPLC). RESULTS Three patients achieved a complete response (CR) and 10 patients a partial response for an objective response rate of 41% (95% confidence interval, 24% to 58%). The median survival was 4 months (range, 1 to 23). Neutropenia was dose-limiting, and two patients died of neutropenic sepsis. Pharmacodynamic correlations for drug concentrations and hematologic toxicities were available for 27 patients and a total of 76 treatment courses, and correlations were significant for graded hematologic toxicity and nadir counts of leukocytes, neutrophils, hemoglobin, and platelets. The grade of infection (77 courses) was also related to drug levels. Using data from 27 initial courses, a pharmacodynamic model was developed to estimate the nadir leukocyte or neutrophil count (WBCn, ANCn) based on the pretreatment count (WBCp, ANCp) and the etoposide concentration (Ec) as follows: WBCn = 0.35 (1 + WBCp x e-1.12 x Ec) and ANCn = 0.32 (1 + ANCp x e-2.47 x Ec). CONCLUSION Etoposide concentrations are related to the resulting hematologic toxicities. It is possible to predict nadir counts in the first course by a pharmacodynamic model. The above equations need to be validated prospectively and may be useful in future studies of prolonged oral etoposide.
Collapse
Affiliation(s)
- A A Miller
- Veterans Affairs Medical Center, Memphis, TN
| | | | | | | | | |
Collapse
|